SCHEMBL5283948

SCHEMBL5283948

NC(C(=O)Oc1c(F)c(F)c(F)c(F)c1F)S(=O)(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 1/20 0.36
CA7 P43166 2/20 0.36
CA13 Q8N1Q1 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
BCAT1 P54687 1/20 0.35
SLC1A3 P43003 2/20 0.35
SLC1A2 P43004 2/20 0.35
SLC1A1 P43005 2/20 0.35
LARS1 Q9P2J5 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 1/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5281607 0.79 KMT2A (0.47) ATMTDP1CA12CA1CA2
SCHEMBL11883834 0.73 SLC1A3 (0.49) TDP1CA12CA1CA2CA9
SCHEMBL3243611 0.72 ATM (0.37) ATMCA12CA1CA2CA9
SCHEMBL8990144 0.71 ALPI (0.54) SLC1A3SLC1A2SLC1A1
SCHEMBL3246102 0.71 CYP3A4 (0.47) ATMCA12CA1CA2CA9
SCHEMBL8990136 0.71 ALPI (0.54) SLC1A3SLC1A2SLC1A1
SCHEMBL20591944 0.70 L3MBTL1 (0.67) TDP1L3MBTL1LMNAHSD17B10KMT2A
SCHEMBL19105466 0.70 L3MBTL1 (0.49) ATMTDP1L3MBTL1LMNATSHR
Hydrochloric Acid SCHEMBL3050574 0.70 ALPI (0.53) SLC1A3SLC1A2SLC1A1
SCHEMBL27548068 0.70 SLC1A3 (0.42) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 ATM 4711/4885TDP1 2633/4885CA12 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.